Skip to main content

Table 1 Amelioration of experimental autoimmune encephalomyelitis (EAE) by Fn14·TRAIL

From: Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14·TRAIL

Treatment

Disease mean severity

Vehicle

2.4 ± 0.2

Fn14·TRAIL 25 μg/day (14-day treatment)

2.3 ± 0.2

Fn14·TRAIL 50 μg/day (14-day treatment)

1.6 ± 0.1*

Fn14·TRAIL 100 μg/day (14-day treatment)

1.5 ± 0.1*

Fn14·TRAIL 200 μg/day (14-day treatment)

1.2 ± 0.1*

Fn14·TRAIL 200 μg/day (7-day treatment)

1.4 ± 0.3*

Fn14·TRAIL 200 μg/day (4-day treatment)

1.2 ± 0.3*

  1. The data are expressed as mean disease score ± SE, in 21 control-vehicle treated mice, and in 10 mice in each treatment group. Treatment started from day 10 post-induction and lasted for the time periods indicated. *P <0.05 versus control.
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094